Research press release


Nature Medicine

Cancer killing virus shows promise for liver cancer


JX-594はワクシニアウイルスを改変したもので、David Kimたちは、これを用いて第1相臨床試験(初めての投与量設定試験)を行い、このウイルスで抗腫瘍免疫応答を誘導できることを証明した。このウイルスを高用量投与した肝細胞がん(HCC)患者の平均生存期間は、低用量投与群が6.7か月であるのに比べ、14.1か月になることがわかった。


Evidence of a dose dependent therapeutic effect from the JX-594 virus that infects and kills tumor cells in patients with advanced liver cancer is reported in a study published online this week in Nature Medicine.

JX-594 is a modified vaccinia virus. While Phase 1 studies had been performed using the virus, David Kirn and colleagues report the first dose-finding study of JX-594 and evidence that it can induce antitumor immune responses. The authors found that for patients with hepatocellular carcinoma (HCC) that received the high dose of virus, median survival was 14.1 months, compared with 6.7 months for patients receiving the low dose arm.

These results must be confirmed in larger placebo controlled trials and further studies will be necessary to fully ascertain the mechanisms of protective efficacy of JX-594, though these results do offer hope for a new approach to tumor treatment.

doi: 10.1038/nm.3089


メールマガジンリストの「Nature 関連誌今週のハイライト」にチェックをいれていただきますと、毎週各ジャーナルからの最新の「注目のハイライト」をまとめて皆様にお届けいたします。